Lv11
20 积分 2025-11-03 加入
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
1小时前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
1小时前
已完结
OnabotulinumtoxinA for the Treatment of Poststroke Distal Lower Limb Spasticity: A Randomized Trial
15天前
已完结
Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma
26天前
已完结
Treatment for hepatocellular carcinoma after immunotherapy
26天前
已完结
Trials in intracerebral haemorrhage: a path to success?
1个月前
已完结
Traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised, placebo-controlled, double-blind, clinical trial
1个月前
已完结
Traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised, placebo-controlled, double-blind, clinical trial
1个月前
已完结
BCL-2 inhibition in Waldenström macroglobulinaemia and marginal zone lymphoma
1个月前
已完结
The Treatment of Marginal Zone Lymphoma
1个月前
已完结
皖公网安备34019202002308
